Merck Shares Consolidate Near Record Highs as Investors Weigh Vaccine Data and Valuation

Merck & Co. (MRK) shares are consolidating just below a recent all-time high, following a significant rally sparked by positive late-stage trial data for its personalized cancer vaccine. The stock hit a record $154.49 on August 21 before easing to $149.54 by the close on August 27, a pullback of about 3.2%.

Analyst Ratings Diverge After Trial Success

The primary catalyst for the stock's +12% surge on August 19 was an announcement that its mRNA cancer vaccine, intismeran, met both primary and secondary endpoints in a Phase 3 trial. The vaccine, co-developed with Moderna (MRNA), was tested as an adjuvant treatment for melanoma in combination with Merck's blockbuster drug, Keytruda.

The positive data prompted a wave of analyst price target revisions, though opinions on further upside are mixed:

• Morgan Stanley reiterated an Overweight rating, raising its price target to $179 from $116.
• BMO Capital maintained a Buy rating, increasing its target to $170 from $142.
• UBS downgraded the stock to Neutral from Buy, setting a $150 price target and noting the stock's recent move was "broadly aligned with events."

Valuation and Financial Health

Ad

Following the sharp price increase, valuation has become a central focus for investors. According to fair value models cited by Investing.com, Merck's intrinsic value is estimated at $148.02, suggesting the stock is now fully priced after its recent run.

Key financial metrics reflect a mixed picture. The company's forward price-to-earnings (P/E) ratio stands at a high 55.7x. While Merck offers a 2.3% dividend yield and has a 15-year history of consecutive increases, its debt-to-equity ratio is a moderately high 128.6%.

Upcoming Catalyst and Market Outlook

Market participants are now looking ahead to the next major catalyst: the presentation of full intismeran data at the European Society for Medical Oncology (ESMO) 2026 conference in Madrid on October 26-27. This event is seen as a significant inflection point for the stock.

The bull case hinges on intismeran's potential to address multiple oncology indications, with peak sales estimated at over $9.2 billion, which would help cushion the impact of Keytruda's expected patent expiration around 2028. Conversely, bears point to the stock's rich valuation and downward earnings revisions from 13 analysts for the upcoming period. From a technical perspective, the stock is holding near a key support level of $149.49.